risk of recurrence. Those deemed at high risk for distant recurrence despite adjuvant endocrine therapy may also receive adjuvant chemotherapy. The decision whether to administer adjuvant chemotherapy in patients with HR+/HER2− tumors is based on many
Search Results
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021
Featured Updates to the NCCN Guidelines
William J. Gradishar, Meena S. Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Steven J. Isakoff, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Jennifer Matro, Ingrid A. Mayer, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Kari B. Wisinski, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
Presenter: Christopher G. Willett
surgery versus LCCRT, surgery, and adjuvant chemotherapy. 4 With SCRT followed by chemotherapy, the rate of R0 resections (primary endpoint) trended favorably ( P =.07) and acute toxicity was less ( P =.006), but late complications were similar. SCRT also
Gary H. Lyman
body-mass index . Lancet 2005 ; 366 : 1108 – 1110 . 27 Hershman DL Wang X McBride R . Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women . Breast Cancer Res Treat 2006 ; 99 : 313 – 321
Clayton A. Smith and Lisa A. Kachnic
significant benefit to overall survival (OS). 4 Adjuvant chemotherapy both reduced the rate of distant metastases and improved disease-free survival (DFS). 5 , 6 This review focuses on the current treatment paradigms for LARC and highlights clinical trials
Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi
benefit in patients treated with multiagent regimens. 16 , 19 There have been no studies to date directly comparing neoadjuvant versus adjuvant chemotherapy, each of which has advantages and disadvantages. Given these data, the NCCN Clinical Practice
Fei Gao, Nan Li, YongMei Xu, and GuoWang Yang
points. According to the inclusion criteria in our study, we selected patients pathologically diagnosed with stage IIIA non–small cell lung cancer (NSCLC) in 2010 through 2015. According to the NCCN Guidelines, adjuvant chemotherapy is strongly
Carmen P. Escalante, Ellen Manzullo, and Rosalie Valdres
and correlates of fatigue after adjuvant chemotherapy for breast cancer . J Clin Oncol 1998 ; 16 : 1689 – 1696 . 9 Mendoza TR Wang XS Cleeland CS The rapid assessment of fatigue in cancer patients . Cancer 1999 ; 85 : 1186
Junmiao Wen and Donglai Chen
into 5 subgroups: surgery alone, surgery plus adjuvant chemotherapy with or without radiotherapy, neoadjuvant chemotherapy with or without radiotherapy plus surgery and adjuvant chemotherapy with or without radiotherapy, concurrent chemoradiotherapy
Ali Raza Khaki, V.K. Gadi, and Vinay Prasad
Multiple predictive assays have been implemented into clinical practice to help determe which women with early-stage hormone-sensitive breast cancer may benefit from adjuvant chemotherapy and which may not. These assays were originally developed as
Shaneli A. Fernando and Stephen B. Edge
adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic
